Christos Liatsos

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Impact of Helicobacter pylori eradication on the progression of Correa's cascade.

Impact of Helicobacter pylori eradication on the progression of Correa's cascade.

Journal: Annals of gastroenterology

Published: January 30, 2026

Predictors of Response to Induction Therapy with Ustekinumab in Patients with Ulcerative Colitis: Results from a National Study in Greece.

Predictors of Response to Induction Therapy with Ustekinumab in Patients with Ulcerative Colitis: Results from a National Study in Greece.

Journal: Diseases (Basel, Switzerland)

Published: January 25, 2026

Potential Influence of Helicobacter Pylori on Glaucoma-Related Alterations of Ocular Surface Microbiota and Dry Eye Disease Pathophysiology.

Potential Influence of Helicobacter Pylori on Glaucoma-Related Alterations of Ocular Surface Microbiota and Dry Eye Disease Pathophysiology.

Journal: Investigative ophthalmology & visual science

Published: January 14, 2026

Helicobacter pylori Infection as a Potential Risk Factor for Barrett's Esophagus.

Helicobacter pylori Infection as a Potential Risk Factor for Barrett's Esophagus.

Journal: Journal of gastroenterology and hepatology

Published: December 28, 2025

A potential impact of Helicobacter pylori-related metabolic syndrome on the course of high-grade dysplasia in Barrett's esophagus.

A potential impact of Helicobacter pylori-related metabolic syndrome on the course of high-grade dysplasia in Barrett's esophagus.

Journal: Gastrointestinal endoscopy

Published: September 25, 2025

The Potential Role of Helicobacter pylori-Related Mast Cell Activation in the Progression from Gastroesophageal Reflux to Barrett's Esophagus and Esophageal Adenocarcinoma.

The Potential Role of Helicobacter pylori-Related Mast Cell Activation in the Progression from Gastroesophageal Reflux to Barrett's Esophagus and Esophageal Adenocarcinoma.

Journal: Microorganisms

Published: July 03, 2025

Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study.

Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study.

Journal: World journal of gastroenterology

Published: July 01, 2025

Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study.

Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study.

Journal: European journal of gastroenterology & hepatology

Published: February 27, 2025

Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission.

Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission.

Journal: Frontiers in medicine

Published: February 25, 2025

Efficacy and safety of tofacitinib for the treatment of moderate-to-severe ulcerative colitis in biologic-naive patients.

Efficacy and safety of tofacitinib for the treatment of moderate-to-severe ulcerative colitis in biologic-naive patients.

Journal: European journal of gastroenterology & hepatology

Published: February 20, 2025

Pregnancy outcomes in Greek women with inflammatory bowel disease: a longitudinal national retrospective study.

Pregnancy outcomes in Greek women with inflammatory bowel disease: a longitudinal national retrospective study.

Journal: European journal of gastroenterology & hepatology

Published: September 26, 2024

Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease.

Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease.

Journal: Alimentary pharmacology & therapeutics

Published: July 04, 2024

Showing 1-12 of 70

Last Updated: 09/26/2026